Last reviewed · How we verify
Anti-inflammatory drug — Competitive Intelligence Brief
phase 3
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-inflammatory drug (Anti-inflammatory drug) — Maastricht University Medical Center. An anti-inflammatory drug that reduces inflammatory pathways to treat inflammatory conditions.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-inflammatory drug TARGET | Anti-inflammatory drug | Maastricht University Medical Center | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-inflammatory drug CI watch — RSS
- Anti-inflammatory drug CI watch — Atom
- Anti-inflammatory drug CI watch — JSON
- Anti-inflammatory drug alone — RSS
Cite this brief
Drug Landscape (2026). Anti-inflammatory drug — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-inflammatory-drug. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab